search
Back to results

Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention (RECOVE)

Primary Purpose

Covid19, Post-COVID-19 Syndrome

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Exercise
Inspiratory muscle training
Controls
Sponsored by
Universidad de Murcia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Covid19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen >90 days before randomization.
  • Still present a chronic symptomatic phase lasting >90 days since debut of symptoms
  • Have not been hospitalized
  • There is no evidence on clinical records of pneumonia or any other organ failure related to SARS-CoV-2
  • Non-coincident participation in any intervention trial
  • Capable and willing to provide an informed consent

Exclusion Criteria:

  • Refusal to participate expressed by patient or legally authorized representative if they are present
  • Pregnancy or breast-feeding.
  • Acute heart attack (recent 3-6 months) or unstable angina
  • Uncontrolled atrial or ventricular arrhythmias
  • Aortic dissecting aneurysm
  • Severe aortic stenosis
  • Acute endocarditis / pericarditis
  • Uncontrolled high blood pressure (>180/100 mmHg)
  • Acute thromboembolism
  • Acute or severe heart failure
  • Acute or severe respiratory failure
  • Uncontrolled acute decompensated diabetes mellitus or low blood sugar
  • A recent fracture in the last month.
  • Conditions preventing cooperation

Sites / Locations

  • Faculty of Sport Sciences

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Exercise

Inspiratory muscle training

Controls

Arm Description

Supervised exercise training

Non-supervised inspiratory muscle training protocol

Non-supervised WHO exercise guidelines

Outcomes

Primary Outcome Measures

Changes in subject clinical status
Post-COVID Functional Status (PCFS) on a 5-point ordinal scale (0 to 4 grades) and medical screening

Secondary Outcome Measures

Changes in cardiovascular fitness: Maximal oxygen consumption (VO2max)
VO2max estimated from standard algorithms using a submaximal multistage and individualized cardiopulmonary exercise test on cycloergometer. Heart rate (HR), rate of perceive effort (RPE) and load (W) will be combined to report VO2max in mml/kg/min.
Changes in neuromuscular performance during resistance exercise: Barbell Mean Propulsive Velocity (MPV)
Barbell displacement and velocity will be monitored in real time using a linear transductor during a progressive resistance training exercise tests. Displacement and velocity will be combined to report MPV
Changes in balance: center of pressure (COP) sway
COP sway during a balance test will be measured using a high resolution force plate
Changes in pulmonary function: Forced Vital Capacity (FVC)
The total amount of air exhaled (mL) during a forced expiratory volume test will be measured by spirometry.
Changes in pulmonary function: Forced expiratory volume (FEV)
The amount of air exhaled (mL) during the first (FEV1), second (FEV2), and third seconds (FEV3) of the forced breath will be measured by spirometry.
Changes in high sensitivity C-reactive protein (hsCPR)
hsCPR (mg/L) determined by blood-based biochemistry analysis
Changes in D-dimer
D-dimer (mg/L) determined by blood-based biochemistry analysis
Changes in Troponin
Troponin (ng/mL) determined by blood-based biochemistry analysis
Changes in glutamic-pyruvic transaminase (GPT)
GPT(IU/L) determined by blood-based biochemistry analysis
Changes in serum creatine kinase (CK)
CK (U/L) determined by blood-based biochemistry analysis lactate dehydrogenase (LDH)
Changes in lactate dehydrogenase (LDH)
LDH (U/L) determined by blood-based biochemistry analysis
Changes in physical activity levels
Metabolic Equivalents (METs) throughout a week, including activity for work, during transport and leisure time, using the self-reported general physical activity questionnaire (GPAQ)
Changes in tolerance to exercise: DePaul Symptom Questionnaire for Post-exertional malaise (DSQ-PEM) scores
DSQ-PEM will be administrate to obtain a score of tolerance to exercise (DSQ-PEM Scoring depends on the 10-item mixed questionnaire including scale and yes/no questions)
Changes in fatigue: Chalder Fatigue Scale scale (CFQ-11)
CFQ-11 will be administrate to obtain a score of fatigue (Each of the 11 items are answered on a 4-point scale ranging from the asymptomatic to maximum symptomology)
Changes in anxiety: Generalized Anxiety Disorder scale (GAD7)
GAD7 will be administrate to obtain a score of anxiety status (total score for the seven items ranges from 0 to 21)
Changes in depression: Patient Health Questionnaire (PHQ9)
PHQ9 will be administrate to obtain a score of depression status (total score for the nine items ranges from 0 to 27)
Changes in health related quality of life: 12-item Short Form Survey (SF12)
Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The scores will be reported as Z-scores (difference compared to the population average, measured in standard deviations).

Full Information

First Posted
January 16, 2021
Last Updated
August 16, 2022
Sponsor
Universidad de Murcia
search

1. Study Identification

Unique Protocol Identification Number
NCT04718506
Brief Title
Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention
Acronym
RECOVE
Official Title
Rehabilitation for Post-COVID-19 Syndrome Through a Multicomponent, Educational and Supervised Exercise Intervention [RECOVE]
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
January 12, 2021 (Actual)
Primary Completion Date
February 6, 2022 (Actual)
Study Completion Date
May 27, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Murcia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a randomized controlled trial of the efficacy of a tailored exercise program, based on multicomponent exercise training and/or inspiratory muscle training, compared to the WHO self-management leaflet commonly used in outpatient scenarios, on the recovery of persistent symptoms and functional limitations after COVID-19. . The primary objective of the study is to evaluate the clinical efficacy and safety of a tailored exercise-based treatment relative to the control arm in improving the subject clinical status in ambulatory patients.
Detailed Description
A fraction ~10% of the COVID-19 patients who undergo a variable acute symptomatic phase of the disease are coming forward with continuing effects of the disease over a month, with chronic complaints like mental fog, delayed latent periods in recalling events of recent past, tachycardia, extreme fatigue, inability to perform daily physical tasks and likely to develop stress, depression, irritability, insomnia, fear, confusion, anger and frustration. This condition is defined as post-COVID-19 syndrome and increasingly affecting a high number of people as the pandemic evolves. The post-COVID-19 syndrome has become a usual situation in the evolutionary course of the disease with its own entity. The National Health Service (NHS) of UK has recently published a clinical guide for long-term management of the effects of COVID-19 with a comprehensive plan for the assessment and care of patients who present or develop symptoms from the fourth week after diagnosis. The effective long-term management of the effects of COVID-19 is a challenge that requires awareness. The RECOVE project aims at determining the role of exercise in the treatment of post-COVID-19 syndrome ambulatory patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19, Post-COVID-19 Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
83 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercise
Arm Type
Experimental
Arm Description
Supervised exercise training
Arm Title
Inspiratory muscle training
Arm Type
Experimental
Arm Description
Non-supervised inspiratory muscle training protocol
Arm Title
Controls
Arm Type
Active Comparator
Arm Description
Non-supervised WHO exercise guidelines
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Intervention Description
Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises [squat, bench press, deadlift and bench pull]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences
Intervention Type
Behavioral
Intervention Name(s)
Inspiratory muscle training
Intervention Description
Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets
Intervention Type
Behavioral
Intervention Name(s)
Controls
Intervention Description
Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
Primary Outcome Measure Information:
Title
Changes in subject clinical status
Description
Post-COVID Functional Status (PCFS) on a 5-point ordinal scale (0 to 4 grades) and medical screening
Time Frame
Baseline to 8 Weeks
Secondary Outcome Measure Information:
Title
Changes in cardiovascular fitness: Maximal oxygen consumption (VO2max)
Description
VO2max estimated from standard algorithms using a submaximal multistage and individualized cardiopulmonary exercise test on cycloergometer. Heart rate (HR), rate of perceive effort (RPE) and load (W) will be combined to report VO2max in mml/kg/min.
Time Frame
Baseline to 8 Weeks
Title
Changes in neuromuscular performance during resistance exercise: Barbell Mean Propulsive Velocity (MPV)
Description
Barbell displacement and velocity will be monitored in real time using a linear transductor during a progressive resistance training exercise tests. Displacement and velocity will be combined to report MPV
Time Frame
Baseline to 8 Weeks
Title
Changes in balance: center of pressure (COP) sway
Description
COP sway during a balance test will be measured using a high resolution force plate
Time Frame
Baseline to 8 Weeks
Title
Changes in pulmonary function: Forced Vital Capacity (FVC)
Description
The total amount of air exhaled (mL) during a forced expiratory volume test will be measured by spirometry.
Time Frame
Baseline to 8 Weeks
Title
Changes in pulmonary function: Forced expiratory volume (FEV)
Description
The amount of air exhaled (mL) during the first (FEV1), second (FEV2), and third seconds (FEV3) of the forced breath will be measured by spirometry.
Time Frame
Baseline to 8 Weeks
Title
Changes in high sensitivity C-reactive protein (hsCPR)
Description
hsCPR (mg/L) determined by blood-based biochemistry analysis
Time Frame
Baseline to 8 Weeks
Title
Changes in D-dimer
Description
D-dimer (mg/L) determined by blood-based biochemistry analysis
Time Frame
Baseline to 8 Weeks
Title
Changes in Troponin
Description
Troponin (ng/mL) determined by blood-based biochemistry analysis
Time Frame
Baseline to 8 Weeks
Title
Changes in glutamic-pyruvic transaminase (GPT)
Description
GPT(IU/L) determined by blood-based biochemistry analysis
Time Frame
Baseline to 8 Weeks
Title
Changes in serum creatine kinase (CK)
Description
CK (U/L) determined by blood-based biochemistry analysis lactate dehydrogenase (LDH)
Time Frame
Baseline to 8 Weeks
Title
Changes in lactate dehydrogenase (LDH)
Description
LDH (U/L) determined by blood-based biochemistry analysis
Time Frame
Baseline to 8 Weeks
Title
Changes in physical activity levels
Description
Metabolic Equivalents (METs) throughout a week, including activity for work, during transport and leisure time, using the self-reported general physical activity questionnaire (GPAQ)
Time Frame
Baseline to 8 Weeks
Title
Changes in tolerance to exercise: DePaul Symptom Questionnaire for Post-exertional malaise (DSQ-PEM) scores
Description
DSQ-PEM will be administrate to obtain a score of tolerance to exercise (DSQ-PEM Scoring depends on the 10-item mixed questionnaire including scale and yes/no questions)
Time Frame
Baseline to 8 Weeks
Title
Changes in fatigue: Chalder Fatigue Scale scale (CFQ-11)
Description
CFQ-11 will be administrate to obtain a score of fatigue (Each of the 11 items are answered on a 4-point scale ranging from the asymptomatic to maximum symptomology)
Time Frame
Baseline to 8 Weeks
Title
Changes in anxiety: Generalized Anxiety Disorder scale (GAD7)
Description
GAD7 will be administrate to obtain a score of anxiety status (total score for the seven items ranges from 0 to 21)
Time Frame
Baseline to 8 Weeks
Title
Changes in depression: Patient Health Questionnaire (PHQ9)
Description
PHQ9 will be administrate to obtain a score of depression status (total score for the nine items ranges from 0 to 27)
Time Frame
Baseline to 8 Weeks
Title
Changes in health related quality of life: 12-item Short Form Survey (SF12)
Description
Two summary scores are reported from the SF-12 - a mental component score (MCS-12) and a physical component score (PCS-12). The scores will be reported as Z-scores (difference compared to the population average, measured in standard deviations).
Time Frame
Baseline to 8 Weeks
Other Pre-specified Outcome Measures:
Title
Changes in Percent Body Fat
Description
Body composition will be measured by bioelectrical impedance analysis
Time Frame
Baseline to 8 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen >90 days before randomization. Still present a chronic symptomatic phase lasting >90 days since debut of symptoms Have not been hospitalized There is no evidence on clinical records of pneumonia or any other organ failure related to SARS-CoV-2 Non-coincident participation in any intervention trial Capable and willing to provide an informed consent Exclusion Criteria: Refusal to participate expressed by patient or legally authorized representative if they are present Pregnancy or breast-feeding. Acute heart attack (recent 3-6 months) or unstable angina Uncontrolled atrial or ventricular arrhythmias Aortic dissecting aneurysm Severe aortic stenosis Acute endocarditis / pericarditis Uncontrolled high blood pressure (>180/100 mmHg) Acute thromboembolism Acute or severe heart failure Acute or severe respiratory failure Uncontrolled acute decompensated diabetes mellitus or low blood sugar A recent fracture in the last month. Conditions preventing cooperation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Javier Courel-Ibáñez, Ph.D
Organizational Affiliation
Faculty of Sport Sciences, University of Murcia, Spain.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Amaya Jimeno-Almazán, Dr,
Organizational Affiliation
University Hospital of Santa Lucía, Infectious Diseases Section,
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jesús García Pallarés, Ph.D
Organizational Affiliation
Faculty of Sport Sciences, University of Murcia, Spain.
Official's Role
Study Director
Facility Information:
Facility Name
Faculty of Sport Sciences
City
Murcia
State/Province
San Javier
ZIP/Postal Code
30720
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention

We'll reach out to this number within 24 hrs